Clinical Study

Pretreatment Diffusion-Weighted MRI Can Predict the Response to Neoadjuvant Chemotherapy in Patients with Nasopharyngeal Carcinoma

Table 3

Tumor volume and ADCs of the primary tumor and metastatic adenopathies in 92 patients with NPC.

Characteristic Number of patients-value
Responders () Nonresponders ()

Tumor volume (cm3)
 NP pretreatment37.3 ± 2.736.2 ± 7.00.884
 NP posttreatment9.1 ± 1.2 23.7 ± 4.70.010
 LN pretreatment18.2 ± 1.7 20.0 ± 4.60.708
 LN posttreatment2.4 ± 0.514.3 ± 3.10.004
ADC (×10−3 mm2/sec)
 NP pretreatment0.809 ± 0.0090.953 ± 0.0380.003
 NP posttreatment1.276 ± 0.0071.306 ± 0.0330.182
 LN pretreatment 0.966 ± 0.010 1.121 ± 0.0450.007
 LN posttreatment1.354 ± 0.0091.355 ± 0.0450.983
Increase in ADC (%)
 NP 58.5 ± 1.038.2 ± 3.1 <0.001
 LN40.4 ± 0.521.2 ± 1.3<0.001

NP = nasopharynx; LN = regional neck lymph nodes.